201 related articles for article (PubMed ID: 36094141)
41. Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: A retrospective cross-sectional study.
Obakiro SB; Kiyimba K; Napyo A; Kanyike AM; Mayoka WJ; Nnassozi AG; Aguti B; Akech GM; Waako JP
PLoS One; 2021; 16(1):e0245036. PubMed ID: 33400703
[TBL] [Abstract][Full Text] [Related]
42. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
43. The right to health as the basis for universal health coverage: A cross-national analysis of national medicines policies of 71 countries.
Perehudoff SK; Alexandrov NV; Hogerzeil HV
PLoS One; 2019; 14(6):e0215577. PubMed ID: 31251737
[TBL] [Abstract][Full Text] [Related]
44. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Cherny NI; Sullivan R; Torode J; Saar M; Eniu A
Ann Oncol; 2017 Nov; 28(11):2633-2647. PubMed ID: 28950323
[TBL] [Abstract][Full Text] [Related]
45. Real-world challenges for patients with breast cancer in sub-Saharan Africa: a retrospective observational study of access to care in Ghana, Kenya and Nigeria.
Twahir M; Oyesegun R; Yarney J; Gachii A; Edusa C; Nwogu C; Mangutha G; Anderson P; Benjamin E; Müller B; Ngoh C
BMJ Open; 2021 Mar; 11(3):e041900. PubMed ID: 33653746
[TBL] [Abstract][Full Text] [Related]
46. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
[TBL] [Abstract][Full Text] [Related]
47. Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study.
Onyango MA; Vian T; Hirsch I; Salvi DD; Laing R; Rockers PC; Ashigbie PG; Wirtz VJ
PLoS One; 2018; 13(8):e0201917. PubMed ID: 30142218
[TBL] [Abstract][Full Text] [Related]
48. Cancer Medicines: What Is Essential and Affordable in India?
Sengar M; Fundytus A; Hopman W; Pramesh CS; Radhakrishnan V; Ganesan P; Mathew A; Lombe D; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
JCO Glob Oncol; 2022 Jul; 8():e2200060. PubMed ID: 35853192
[TBL] [Abstract][Full Text] [Related]
49. Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country.
Fathi M; Moradi N; Yousefi N; Peiravian F; Shobeiri N
BMC Pulm Med; 2023 Nov; 23(1):429. PubMed ID: 37925396
[TBL] [Abstract][Full Text] [Related]
50. Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.
Beran D; Ewen M; Lipska K; Hirsch IB; Yudkin JS
Curr Diab Rep; 2018 Jun; 18(8):48. PubMed ID: 29907884
[TBL] [Abstract][Full Text] [Related]
51. Affordability of comprehensive community health worker programmes in rural sub-Saharan Africa.
Taylor C; Griffiths F; Lilford R
BMJ Glob Health; 2017; 2(3):e000391. PubMed ID: 29018584
[TBL] [Abstract][Full Text] [Related]
52. Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda.
Rurangwa C; Ndayisenga J; Sezirahiga J; Nyirimigabo E
BMC Health Serv Res; 2023 Jun; 23(1):717. PubMed ID: 37391753
[TBL] [Abstract][Full Text] [Related]
53. Effects of scaling up various community-level interventions on child mortality in Burundi, Kenya, Rwanda, Uganda and Tanzania: a modeling study.
Hategeka C; Tuyisenge G; Bayingana C; Tuyisenge L
Glob Health Res Policy; 2019; 4():1. PubMed ID: 31168481
[TBL] [Abstract][Full Text] [Related]
54. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
55. Availability, Costs and Stock-Outs of Essential NCD Drugs in Three Rural Rwandan Districts.
Mukundiyukuri JP; Irakiza JJ; Nyirahabimana N; Ng'ang'a L; Park PH; Ngoga G; El-Khatib Z; Nditunze L; Dusengeyezu E; Rusangwa C; Mpunga T; Mubiligi J; Hedt-Gauthier B
Ann Glob Health; 2020 Sep; 86(1):123. PubMed ID: 33024709
[TBL] [Abstract][Full Text] [Related]
56. Anticancer medicines in Pakistan: An analysis of essential medicines lists.
Shukar S; Anjum R; Zhang J; Babar ZU; Mobeen I; Yang C
J Oncol Pharm Pract; 2024 Jan; 30(1):46-54. PubMed ID: 37006130
[TBL] [Abstract][Full Text] [Related]
57. Universal health coverage in Rwanda: dream or reality.
Nyandekwe M; Nzayirambaho M; Baptiste Kakoma J
Pan Afr Med J; 2014; 17():232. PubMed ID: 25170376
[TBL] [Abstract][Full Text] [Related]
58. Progress towards the 2020 fast track HIV/AIDS reduction targets across ages in Ethiopia as compared to neighboring countries using global burden of diseases 2017 data.
Mirkuzie AH; Ali S; Abate E; Worku A; Misganaw A
BMC Public Health; 2021 Feb; 21(1):285. PubMed ID: 33541303
[TBL] [Abstract][Full Text] [Related]
59. Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda.
Rubagumya F; Wilson B; Manirakiza A; Mutabazi E; A Ndoli D; Rudakemwa E; Chamberlin MD; Hopman WM; Booth CM
Oncologist; 2024 Mar; 29(3):e345-e350. PubMed ID: 37897406
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
